About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 4NCT00293176

The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)

To investigate the efficacy and safety of donepezil in individuals with mild cognitive impairment on measures of cognition, global function and behavior.

Lead sponsor: Eisai Inc.•54 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Eisai Inc.

Collaborators

Pfizer

Age

45 - 90 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Memory complaint
•Mini Mental Status Exam (MMSE) score 24-28 inclusive
•General cognition and function performance sufficiently preserved such that a diagnosis of Alzheimer's disease (AD) cannot be made
•Generally healthy and ambulatory
•Sufficiently fluent in English

Exclusion Criteria

•Diagnosis of probable or possible AD
•Neurological disorders
•History of malignant cancers
•Previously have taken donepezil or other acetylcholinesterase (ChE) inhibitors for more than 1 month or in the past 3 months prior to study entry

Related studies

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

NCT06584357 · Mild Cognitive Impairment, Alzheimer's Disease, and more

RECRUITINGEARLY Phase 1

Pharmacological Modulation of Brain Oscillations in Memory Processing

NCT05594017 · Epilepsy, Seizures, and more

Enrolling By Invitation

Digitally-enhanced, Decentralized, Multi-omics Observational Cohort

NCT04701177 · Presymptomatic Disease, Mild Cognitive Impairment, and more

Active Not RecruitingNA

The PorchLight Project

NCT05550727 · Memory Loss, Alzheimer Disease, and more

A Study of HD-tDCS and Cognitive Training to Improve Cognitive Function in MCI

NCT04246164 · Mild Cognitive Impairment, Memory Disorders, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 1, 2011Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment821

Start dateDec 2003

Last updatedApr 1, 2011

Condition

Locations shown

Albaster, Alabama

Mesa, Arizona

Peoria, Arizona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 1, 2011Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions